2005
DOI: 10.1038/sj.cdd.4401610
|View full text |Cite
|
Sign up to set email alerts
|

Carcinogenesis, cancer therapy and chemoprevention

Abstract: Carcinogenesis and cancer therapy are two sides of the same coin, such that the same cytotoxic agent can cause cancer and be used to treat cancer. This review links carcinogenesis, chemoprevention and cancer therapy in one process driven by cytotoxic agents (carcinoagents) that select either for or against cells with oncogenic alterations. By unifying therapy and cancer promotion and by distinguishing nononcogenic and oncogenic mechanisms of resistance, I discuss anticancer-and chemopreventive agent-induced ca… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
67
0

Year Published

2006
2006
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 90 publications
(69 citation statements)
references
References 144 publications
(155 reference statements)
2
67
0
Order By: Relevance
“…Consequently, survival under unfavourable growth conditions may be the outcome of several interactive mechanisms, many of which underlie resistance to chemotherapy when they are mutated in transformed cells and thus multi-targeting therapy has been suggested to abrogate cell survival and to effectively manage resistance (Nicholson et al 2004, Blagosklonny 2005). …”
Section: Crosstalk Between Chemotherapy and The Stress Responsementioning
confidence: 99%
“…Consequently, survival under unfavourable growth conditions may be the outcome of several interactive mechanisms, many of which underlie resistance to chemotherapy when they are mutated in transformed cells and thus multi-targeting therapy has been suggested to abrogate cell survival and to effectively manage resistance (Nicholson et al 2004, Blagosklonny 2005). …”
Section: Crosstalk Between Chemotherapy and The Stress Responsementioning
confidence: 99%
“…Utilisation of 'proteotoxic stress overload' as an inducer of cancer cell death is the rationale for the use of proteasome inhibitors such as Velcade®, in the treatment of a variety of cancer types (Neznanov et al 2011;Workman and Davies 2011;Dou and Li 1999). However, while tumour cells show increased sensitivity to enhanced proteotoxic stresses, undergoing cell death more readily than non-transformed cells, tumour cells that persist following these treatments have been shown to characteristically exhibit a more advanced malignant phenotype and may prove problematic in the event of tumour relapse (Blagosklonny 2005a).…”
Section: Introductionmentioning
confidence: 99%
“…For example, similar to BPDE (present study), a garlic-derived cancer chemopreventive agent (diallyl trisulfide) inhibits growth of H460 cells in association with cell cycle arrest and apoptosis induction (Singh, unpublished observations). As postulated by Blagosklonny, 44 the cell cycle arrest and apoptosis induction following exposure of already transformed cells to carcinogens like BPDE may be a natural defense mechanism against cancer progression.…”
Section: Bpde Treatment Caused Apoptotic Cell Death In H460 Cellsmentioning
confidence: 93%